A panel of Italian medical oncologists with expertise in treating patients with NSCLC gathered in a virtual webinar to share and discuss the available treatment options for ALK-positive advanced NSCLC in Italy, with the aim of providing a manuscript from their discussion that may help clinicians in current and future decision making. Here, ALK is linked to non-small cell lung carcinoma.